As of 2026-03-29, the Relative Valuation of Passage Bio Inc (PASG) is (304.54) USD. This relative valuation is based on P/E multiples. With the latest stock price at 6.38 USD, the upside of Passage Bio Inc based on Relative Valuation is -4873.4%.
The range of the Relative Valuation is (271.43) - (324.75) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 19.1x - 25.1x | 22.0x |
| Forward P/E multiples | 19.1x - 22.9x | 21.0x |
| Fair Price | (271.43) - (324.75) | (304.54) |
| Upside | -4354.4% - -5190.2% | -4873.4% |
| Date | P/E |
| 2026-03-17 | -0.52 |
| 2026-03-16 | -0.54 |
| 2026-03-13 | -0.53 |
| 2026-03-12 | -0.57 |
| 2026-03-11 | -0.60 |
| 2026-03-10 | -0.60 |
| 2026-03-09 | -0.62 |
| 2026-03-06 | -0.59 |
| 2026-03-05 | -0.57 |
| 2026-03-04 | -0.60 |
| 2026-03-03 | -0.56 |
| 2026-03-02 | -0.62 |
| 2026-02-27 | -0.64 |
| 2026-02-26 | -0.61 |
| 2026-02-25 | -0.66 |
| 2026-02-24 | -0.65 |
| 2026-02-23 | -0.62 |
| 2026-02-20 | -0.61 |
| 2026-02-19 | -0.64 |
| 2026-02-18 | -0.64 |
| 2026-02-17 | -0.62 |
| 2026-02-13 | -0.62 |
| 2026-02-12 | -0.62 |
| 2026-02-11 | -0.62 |
| 2026-02-10 | -0.66 |
| 2026-02-09 | -0.63 |
| 2026-02-06 | -0.67 |
| 2026-02-05 | -0.64 |
| 2026-02-04 | -0.75 |
| 2026-02-03 | -0.77 |
| 2026-02-02 | -0.85 |
| 2026-01-30 | -0.81 |
| 2026-01-29 | -0.76 |
| 2026-01-28 | -0.80 |
| 2026-01-27 | -0.89 |
| 2026-01-26 | -0.88 |
| 2026-01-23 | -0.89 |
| 2026-01-22 | -0.90 |
| 2026-01-21 | -0.87 |
| 2026-01-20 | -0.90 |
| 2026-01-16 | -0.91 |
| 2026-01-15 | -1.01 |
| 2026-01-14 | -1.07 |
| 2026-01-13 | -1.01 |
| 2026-01-12 | -1.26 |
| 2026-01-09 | -1.40 |
| 2026-01-08 | -1.29 |
| 2026-01-07 | -1.27 |
| 2026-01-06 | -1.30 |
| 2026-01-05 | -1.14 |